Healthcare Industry News: Sanofi-aventis
News Release - May 22, 2009
Marty J. Duvall Joins Abraxis BioScience as Senior Vice President, Global Marketing and International Commercial OperationsLOS ANGELES--(HSMN NewsFeed)--Abraxis BioScience, Inc. (NASDAQ: ABII ), a fully integrated biotechnology company, today announced that Marty J. Duvall has joined the management team as Senior Vice President, Global Marketing and International Commercial Operations.
“Marty has a successful track record of building brands and significantly contributing to the growth of companies in the oncology arena,” said Lonnie Moulder, President and CEO of Abraxis BioScience. “He and his team will be responsible for expanding the ABRAXANE brand franchise, both geographically and by launching new indications. We are very pleased to have this experienced executive join our growing team as we advance our mission to enhance the lives of cancer patients throughout the world.”
Mr. Duvall most recently served as Chief Business Officer, Morphotek, a subsidiary of Eisai Corporation of North America, following Eisai’s acquisition of MGI PHARMA, INC., where he served as Sr. Vice President, Commercial Operations (2004-2006) and Sr. Vice President, Commercial Strategy and Development (2007-2008). Previously, Mr. Duvall served for nearly 19 years in a number of commercial roles at Sanofi-aventis and its predecessor companies. During that tenure, his responsibilities included Vice President, Global Medical and Marketing, with a focus on Taxotere®, and Vice President, Marketing for the U.S. Oncology Business Unit. He earned a bachelor of science degree in chemistry from Muhlenberg College, a master degree in chemistry from The Johns Hopkins University, and a master of business administration degree from the University of Kansas.
About Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 36 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.
Source: Abraxis BioScience
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.